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Introduction
Management of iron overload in the setting of post-allogeneic
hematopoietic stem cell transplant (allo-HSCT) may be compli-
cated since the use of therapeutic phlebotomies is often not fea-
sible due to ongoing anemia. Limited but compelling data are
available regarding the use of deferasirox in allo-HSCT recipi-
ents with b-thalassemia.1-6 
Pre-transplant iron overload has been associated with consid-
erable morbidity and increased mortality in patients undergoing
HSCT.7-14 Transfusional hemosiderosis and increased non-trans-
ferrin bound iron result in generation of free radicals that may
eventually cause oxidative organ damage, especially to the liver,
heart and endocrine system. Pre-transplant serum ferritin over
1000 ng/mL has been associated with a higher rate of treat-
ment-related complications such as mucositis, acute graft-ver-
sus-host disease (GvHD), liver dysfunction, chronic liver dis-
ease, exacerbation of chronic GvHD, hepatic sinusoidal obstruc-
tion syndrome (SOS), and bacterial, fungal and viral infections.
Elevated serum ferritin levels prior to transplant have also been
associated with a lower survival rate, and increased overall and
treatment-related mortality in patients undergoing HSCT for
hematologic malignancies.15 In a study of 112 adults who had
undergone allo-HSCT, causes of death within 100 days after
transplant among the patients with high serum ferritin were
infection (29%), organ failure (29%), GvHD (29%) and SOS
(14%).7 Regarding the effects of persistent iron overload on the
long-term morbidity of HSCT survivors, Meyer et al. found that,
in 290 allo-HSCT recipients, hyperferritinemia had a detrimen-
tal effect on post-HSCT survival (0-6 months P<0.001; 6-12
months P<0.001; 1-2 years P=0.02; 2-5 years P=0.002).16
However, because serum ferritin is an imperfect surrogate
measure of iron stores, its prognostic role in patients with a his-
tory of HSCT and iron overload still has to be determined.
Several prospective studies have examined the impact of elevat-
ed liver iron concentration (LIC) as measured by magnetic reso-
nance imaging (MRI) on HSCT outcome. There is still no con-
sensus regarding the relevance of LIC in HSCT, mainly due to
the use of different LIC thresholds.17-21
Here we report our experience with the prospective use of
deferasirox in 30 adults with a variety of hematologic malignan-
cies and transfusional iron overload who survived at least six
months after allo-HSCT. 
Methods 
Study design
This was an open-label, multi-center clinical trial carried out in
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This is the first prospective study of deferasirox in adult allogeneic hematopoietic stem cell transplant recipients with
transfusional iron overload in hematologic malignancies. Patients at least six months post transplant were treated with
deferasirox at a starting dose of 10 mg/kg/day for 52 weeks or until serum ferritin was less than 400 ng/mL on two con-
secutive occasions. Thirty patients were enrolled and 22 completed the study. A significant reduction from baseline in
median serum ferritin and in liver iron concentration at 52 weeks was observed in the overall population: from 1440 to
755.5 ng/mL (P=0.002) and from 14.5 to 4.6 mg Fe/g dw (P=0.0007), respectively. Reduction in serum ferritin in patients
who did not discontinue deferasirox therapy was significantly greater than that found in those who prematurely dis-
continued the treatment (from 1541 to 581 ng/mL vs. from 1416 to 1486 ng/mL; P=0.008). Drug-related adverse events,
reported in 17 patients (56.7%), were mostly mild to moderate in severity. There were no drug-related serious adverse
events. Twelve patients (40.0%) showed an increase of over 33% in serum creatinine compared to baseline and greater
than the upper limit of normal on two consecutive visits. Two patients (6.7%) with active graft-versus-host disease
showed an increase in alanine aminotransferase exceeding 10 times upper limit of normal; both resolved. In this
prospective study, deferasirox provided a significant reduction in serum ferritin and liver iron concentration over one
year of treatment in allogeneic hematopoietic stem cell transplant recipients with iron overload. In addition, the majority
of adverse events related to deferasirox were mild or moderate in severity. (clinicaltrials.gov identifier:01335035).
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ABSTRACT
hematopoietic transplant units in Spain. Eligible subjects were
patients over 18 years of age who had undergone an allo-HSCT at
least six months prior to enrollment, with transfusional iron over-
load (serum ferritin ≥1000 ng/mL or transfusional load ≥20 units
(~100 mL/kg) of packed red blood cells) and absolute neutrophil
count over 1 x 109/L. Exclusion criteria included iron overload not
related to transfusion, uncontrolled hypertension, active viral hepa-
titis, human immunodeficiency virus infection, serum creatinine
over 2 times upper limit of normal (ULN) or creatinine clearance
less than 50 mL/min, significant proteinuria, serum aspartate
aminotransferase over 5 times ULN, active concomitant malignan-
cies and prior use of iron chelators (Online Supplementary Appendix). 
The primary objective of the study was to evaluate the median
change in serum ferritin after 52 weeks of treatment with
deferasirox in patients with iron overload after allo-HSCT.
Secondary objectives were to assess safety of deferasirox, and to
explore the use of hepatic MRI to assess LIC.
Deferasirox (initial dose 10 mg/kg/day) was administered for 52
weeks or until serum ferritin level was 400 ng/mL or under on two
consecutive occasions. Dose reductions based on serum ferritin lev-
els and on safety markers (serum creatinine, urine protein/creati-
nine ratio, liver enzymes, gastrointestinal events, skin rash, hearing
loss, ocular alterations, or change in weight) were allowed. An
increase in deferasirox dose to a maximum of 30 mg/kg/day was
allowed after three months if serum ferritin increased or failed to
decrease by at least 20% from baseline. Additional chelators, alu-
minum-based antacids and vitamin C over 200 mg/day were not
allowed. Assessment of LIC by MRI was performed at selected sites
on the basis of availability of equipment. Analysis of MRI images
was carried out at a centralized site based on gradient echo
sequences.22 
Adverse events were reported by the investigators and recorded
in the case report forms.
The study protocol was reviewed and approved by local institu-
tional review boards and/or ethics committees. The study was con-
ducted according to the Declaration of Helsinki and its amendment.
All patients signed informed consent.
Statistical analysis
Categorical variables were described using frequencies and per-
centages, and quantitative variables by the mean, number of cases,
median, standard deviation and range (minimum and maximum).
Since distribution was not normal (because the result of Shapiro
Wilk normality test for the principal end point, i.e. serum ferritin,
was P<0.05), a non-parametric Wilcoxon test was used for median
change in serum ferritin between baseline and after 52 weeks of
treatment. Evaluations were performed for the intent-to-treat  pop-
ulation
All calculations were performed with SAS for Windows, v.9.1.3
(Cary, NC, USA). Two-sided tests were used; P=0.05 was consid-
ered significant. Safety was assessed in all patients who received at
least one dose of the study drug. The intent-to-treat population
included patients who had received at least one dose of study med-
ication and had at least one base-line and one post-treatment value
of the primary study variable (serum ferritin). In case of missing val-
ues, the method of ‘last observation carried forward’ (LOCF) was
used for the principal variable (serum ferritin). 
Results
Patients
Thirty patients were enrolled from December 2008 to
April 2010. Eight patients discontinued early, prior to com-
pletion of the study, due to: disease progression (n=3), death
(n=2; one disease progression (acute myeloid leukemia) and
one infection (Staphylococcus auriculanis bacteriemia associat-
ed with acute respiratory and multi-organ failure); neither
were considered to be related to the study drug, drug-related
adverse event (n=1; increased serum creatinine), unsatisfac-
tory therapeutic effect (n=1), and withdrawal of consent
(n=1; due to mucositis considered to be related to the study
drug). Twenty-two patients completed the study: 14
patients after 52 weeks of deferasirox, and 8 who achieved
serum ferritin 400 ng/mL or under (on 2 occasions) before
completing 52 weeks of treatment. 
The majority of patients in the series were male (66.7%).
Median age was 46.7 years. Stem cell transplantation was
performed for a range of hematologic malignancies, the
most common of which was acute myeloid leukemia (n=17)
(Table 1). 
At study enrollment, median time since HSCT was 12.2
months (range 6-39 months). Patients had received a mean
43.5 red blood cell units (range 16-112) before start of study.
The conditioning employed included conventional and
reduced intensity regimens. Half of the patients had an unre-
lated donor. Stem cell source was bone marrow or peripher-
al blood in all patients except 5 for whom cord blood was
used. Base-line characteristics are summarized in Table 1. 
Drug exposure
Overall, patients received deferasirox for a median of 45.7
(range 7.9-57.9) weeks (34.8 weeks (range 8.7-57.9) and 51.4
weeks (range 7.9-56) in patients with base-line serum ferritin
<1500 ng/mL and ≥1500 ng/mL, respectively). Dosage was
increased in 5 patients (16.7%) and reduced in 11 (36.7%).
Dose reduction due to increase in serum creatinine occurred
in 9 patients (30%), and due to increase in hepatic enzymes
in 2 patients (6.7%). Treatment was temporarily discontin-
ued in 5 patients due to increased liver enzymes (n=3; 10%),
vomiting (n=1; 3.3%), and hearing disturbances (n=1; 3.3%).
The median time to the first dose adjustment was 15.9
weeks (range 3-44.6). Concomitant use of cyclosporine did
not seem to influence the rate of discontinuation of the
study drug. Among the 8 patients who discontinued
deferasirox, 2 (14.3%) received concomitant cyclosporine
and 6 (37.5%) did not. 
Deferasirox dosage under 10 mg/kg/day (median actual
dose 7 mg/kg/day) was received by 7 patients, 10
mg/kg/day by 18 patients, and over 10 mg/kg/day (median
actual dose 13.4 mg/kg/day) by 5 patients.
Effect of deferasirox on serum ferritin
A significant reduction in median serum ferritin from
baseline to 52 weeks was observed (1444 to 755.5 ng/mL;
P=0.002) in the intent-to-treat population (LOCF).
Significant decreases in median serum ferritin from baseline
were also observed in the 8 patients who met the target
value of 400 ng/mL or under (-1030.0 ng/mL; P=0.0078), and
in the 14 patients who completed 52 weeks of treatment (-
661.5 ng/mL; P=0.0134) (Figure 1). Overall, patients without
premature discontinuation (n=22) had a significant decrease
in median serum ferritin from baseline (-795.5 ng/mL;
P<0.0001) (Figure 2). The 8 patients who discontinued
deferasirox prematurely had no change in median serum fer-
ritin from baseline (Table 2 and Figure 1).
The change in median serum ferritin from baseline to
week 52 was not significant in the 3 patients who contin-
ued to require red blood cell transfusions during the study
(Table 2).
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Base-line and final LIC values were available for 7 patients.
A significant reduction in median LIC from baseline to 52
weeks was observed (from 14.5 to 4.6 mg Fe/g dw;
P=0.007). Among patients with base-line median LIC below
14 mg Fe/g dw, there was a significant decrease from base-
line in median serum ferritin at week 52 (from 1307 to 497
ng/mL; P=0.0156). In patients with base-line LIC 14 mg Fe/g
dw or over there was a non-statistically significant decrease
in serum ferritin (from 2000 to 1528 ng/mL). 
Safety
Adverse events (AEs) were reported in 29 patients
(96.7%). Drug-related AEs, reported in 17 patients (56.7%),
were mostly mild to moderate in severity (Table 3).
Gastrointestinal symptoms (diarrhea, constipation, nausea,
vomiting, and anorexia) were the most frequent AEs
reported.
Nine serious AEs were reported in 8 patients (disease pro-
gression in 3; herpes zoster, respiratory infection, febrile syn-
drome, febrile neutropenia, leukocytosis, and acute massive
subdural hematoma in one each); none were considered
related to the study drug. 
Seven patients presented with active GvHD and 5 with
infection at study enrollment (Table 1). During the study, 8
patients (26.7%) had new infectious episodes and 6 (20.0%)
new evidence of GvHD. None of these events was consid-
ered by the investigators to be related to the study drug. 
During treatment, 5 patients presented with increased
liver transaminases over 4 times ULN; one had active GvHD
at inclusion and 2 developed new episodes of GvHD
through the trial. Two patients, each of whom had active
GvHD at inclusion or presented new episodes of GvHD,
had an increase in alanine aminotransferase (ALT) over 10
times ULN on one occasion. Levels returned to normal in
one patient following temporary discontinuation of the
study drug while the study drug was not modified in the
C. Vallejo et al.
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Table 1. Patients’ base-line characteristics (n=30).
Variable                                                                                 
Male n (%)                                                                                     20 (66.7) 
Age, median (range)                                                             46.7 (20.3-65.3)
Hematologic disease n (%)
Acute myelogenous leukemia                                                  17 (56.7)
Myelodysplastic syndrome                                                        4 (13.4)
Non-Hodgkin lymphoma                                                             3 (10.0)
Aplastic anemia                                                                             2 (6.7)
Acute lymphoblastic leukemia                                                   1 (3.3)
Multiple myeloma                                                                         1 (3.3)
Waldeström macroglobulinemia                                               1 (3.3)
Myelofibrosis                                                                                 1 (3.3)
Infused CD34+ cells (x106/kg)                                               4.0 (0.1-31.0)
median (range)                                                                                   
Active complications of HSCT 
at inclusion, n (%)
GvHD                                                                                               7 (23.3)
Infections                                                                                      5 (16.7)  
Bacterial                                                                                         3 (10.0)
Viral                                                                                                  2 (6.7)
Renal function, median (range)  
Serum creatinine (mg/dL)                                                     1.0 (0.5-1.8)
Creatinine clearance (mL/min)                                       74.6 (40.0-160.0)
Hemoglobin level (g/L) median (range)                            121 (88-164)
Serum ferritin (ng/mL) median (range)                    1444.0 (788.0-4055.0)
LIC., median (range) (mg Fe/g dw) (n=14)                    14.5 (5.6-19.5)
Figure 1. Median serum ferritin based on continuation or not with
study drug. 
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second patient who completed 52 weeks of treatment with
ALT values below 2 times ULN. 
An over 33% increase in serum creatinine compared to
baseline on two consecutive visits and over ULN was
reported in 12 patients (40.0%); 4 of these patients had
base-line serum creatinine above ULN. The increases in
serum creatinine observed in those patients were all below
2 times ULN. Fourteen patients (46.6%) were treated with
cyclosporine A during the study. There was no statistically
significant difference in the incidence of nephrotoxicity in
patients according to concomitant use of cyclosporine [5 of
16 without cyclosporine (31.3%) vs. 7 of 14 patients with
cyclosporine (50%)].
Discussion
This is the first report of a prospective study of deferasirox
in adult patients with hematologic malignancies who have
undergone HSCT. In our study, deferasirox at 10 mg/kg/day
administered for 52 weeks post transplant resulted in a sig-
nificant reduction in median serum ferritin and mean LIC in
22 adult patients who had undergone HSCT at least six
months before. 
Transfusional iron overload is a relatively common com-
plication in hematologic patients and in allo-HSCT recipi-
ents.7,23 Elevated pre-transplant serum ferritin levels have
been associated with increased risk of both overall mortality
and treatment-related mortality in patients undergoing
HSCT, independently of several confounding factors.
Elevated serum ferritin has also been associated with
increased risk of bacterial infection,7,8 mucositis,9 acute
GvHD,10 chronic liver disease,11 and SOS.12,24 However,
because serum ferritin is an imperfect measure of total body
iron, the exact prognostic role of iron overload in allo-HSCT
remains to be determined. Several prospective studies and a
multi-center meta-analysis examining the impact of elevated
LIC on HSCT outcomes came to different conclusions
regarding the prognostic relevance of LIC in HSCT, mainly
due to the use of different LIC thresholds.17-21 However, an
LIC threshold of over 7 mg Fe/g dw has been associated
with a decrease in overall survival and non-relapse
mortality.19,20 In the meta-analysis performed by Armand,
Deferasirox after allogeneic stem cell transplantation
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Table 2. Change from baseline in median serum ferritin.
                                                                             Median serum ferritin (ng/mL)                                         
                                                                      Baseline                       Week 52 LOCF                  Absolute change                              Pa
                                                                       (range)                             (range)                               (range)                                       
Overall, ng/mL, n=30                                                   1444                                         755.5                                          -670.5                                             0.002
                                                                               (788.0 – 4055.0)                      (96.0 – 6128.8)                       (-2210.0-2530.2)                                        
Base-line serum ferritin ng/mL
<1500 ng/mL, n=16                                                      1235                                           448                                           -696.5                                            0.0042
                                                                                 (788.0-1481.0)                         (96.0-1871.0)                          (-1124.0-883.0)
1500-2000 ng/mL, n=6                                                1760.5                                        1242                                          -587.5                                            0.0313
                                                                                (1675.0-1928.0)                       (195.0-1528.5)                        (-1551.0 -167.5)                                         
≥2000 ng/mL, n=8                                                       2163.5                                       1706.5                                          -628                                                  -
                                                                                (2000.0-4055.0)                       (650.0-6128.8)                        (-2210.0-2530.2)                                        
Discontinuation of study drug                                                                                                                                                                                                    
No, n=22                                                                         1541                                           581                                           -795.5                                            0.0001
                                                                                 (788.0-4055.0)                         (96.0-6128.8)                       (-2210.0 – 2530.2)
Yes, n=8                                                                          1416                                          1486                                             -71                                                   -
                                                                                 (809.0-2087.0)                        (513.0-2956.0)                        (-968.0 – 883.0)                                         
LIC at base-line                                                            1307                                           497                                            -1010                                             0.0156
< 14 mg Fe/ g dw, n=7                                       (1119.0-4055.0)                       (241.0-1845.0)                        (-2210.0- -604.0)
≥14 mg Fe/ g dw, n=7                                                  2000                                        1528.5                                          -432                                                  -
                                                                                (1696.0-3598.6)                       (195.0-6128.8)                        (-1551.0-2530.2)                                        
Packed red blood cell transfusions during the study period
No, n=27                                                                       1406.9                                         658                                            - 693                                             0.0018
                                                                                 (788.0-4055.0)                         (96.0-6128.8)                       (-2210.0 – 2530.2)
Yes, n=3                                                                        1928.0                                         853                                             -648                                                  -
                                                                                 (900.0-2695.0)                        (650.0-1280.0)                         (-2045.0- -47.0)                                         
ITT: intent-to-treat; LIC: liver iron concentration; LOCF-last observation carried forward. aStatistically significant differences found between median serum ferritin at Week 52 and
base-line median (Wilcoxon test, P<0.05). 
Table 3. Drug-related adverse events.
Adverse event, n (%)                                        All                  Severe
Serum creatinine increase (> 33%)           11 (36.7%)a                  -
AST and/or ALT increase                                  5 (16.6%)               2 (6.7)
Diarrhea                                                                  2 (6.7)                       -
Constipation                                                          1 (3.3)                       -
Nausea                                                                    1 (3.3)                       -
Vomiting                                                                  1 (3.3)                       -
Rash                                                                         1 (3.3)                       -
Anorexia                                                                  1 (3.3)                       -
Mucositis                                                                1 (3.3)                  1 (3.3)
Hearing disorder                                                  1 (3.3)                       -
Eye discomfort                                                      1 (3.3)                       -
a<2 x ULN in all cases. 
there was a trend towards increased non-relapse mortality
for LIC over 7mg/gdw.21
Data from this trial are based on the analysis of absolute
change in serum ferritin from baseline. Although the assess-
ment of serum ferritin has limitations (e.g. levels can be
increased in conditions of infection and inflammation), it is
simple and inexpensive, and when assessed serially, general-
ly provides a reliable tool to assess total body iron and
response to chelation therapy. In addition, the relationship
between long-term control of serum ferritin and survival has
been clearly demonstrated in cohort studies of chelated
patients with thalassemia major.25 MRI is being increasingly
used to measure iron burden; however, its use in clinical
practice is still limited as the necessary equipment is not
widely available. In our study, 7 patients had LIC analysis by
MRI at baseline and at the end of the trial. 
Initial studies of deferasirox administered following HSCT
to patients with transfusional hemosiderosis have proved
successful.1-6,26-30 Two studies in patients with thalassemia
(one conducted in children) reported no significant differ-
ence in post-treatment serum ferritin levels following
deferasirox versus phlebotomy.1,4 In children, deferasirox
yielded a significant decrease in LIC in patients with base-
line serum ferritin of 1000 ng/mL or over compared to phle-
botomy (-8.1 mg Fe/g dw vs. -3.5 mg Fe/g dw; P=0.048).
Notably, parents of 13 of 14 children randomized to phle-
botomy asked for their child to receive deferasirox because
of issues concerning pain, anemia, and hospitalizations.1 A
small retrospective study of patients with hematologic
malignancies who had undergone HSCT showed that while
both deferasirox and phlebotomy separately were able to
achieve a statistically significant reduction in serum ferritin
from baseline (P=0.017 and P=0.025, respectively), their
combined use resulted in a faster reduction in serum ferritin.5
In this study, the majority of patients received 10
mg/kg/day. This dosage provided a significant reduction in
median serum ferritin from baseline to 52 weeks (from 1444
to 755.5 ng/mL; P=0.002) in the overall population. The
starting dose of deferasirox in the majority of the studies in
HSCT recipients has been 10 mg/kg/day, i.e. lower than that
usually used in the non-transplant setting.1,4,27 However, dose
adjustment for poor response resulted in doses up to 20
mg/kg/day being used in some studies.4,27 In one study, the
mean dose of deferasirox at the last dose was 11 mg/kg/day
in the patients with LIC of 7 mg Fe/g dw or below and 18.1
mg/kg/day in those with LIC over 7 mg Fe/ g dw.1 In our
study, the change in median serum ferritin was not signifi-
cant in 3 patients who continued to require packed red
blood cell transfusions during the study, implying that this
subgroup of patients needed higher doses of deferasirox or
more time under treatment to show a significant decrease in
serum ferritin. Also, in patients with base-line LIC of 14 mg
Fe/g dw or over there was a non-statistically significant
decrease in serum ferritin (from 2000 to 1528 ng/mL). As
with the previous subgroup, those patients with higher
base-line LIC likely needed a higher dose of deferasirox or a
longer duration of treatment.
The safety profile of deferasirox in our study, as in other
experiences with HSCT recipients, was similar to that seen
in patients with non-malignant transfusional
hemosiderosis.1-6,26-30 The most frequent drug-related AEs
were increased creatinine levels, increased transaminases,
and gastrointestinal symptoms, which were generally mild
to moderate in severity.1,4,5,27 
In this report, the increases in serum creatinine were all
below 2 times ULN. Patients taking cyclosporine did not
have a higher incidence of increased serum creatinine com-
pared with patients who did not receive cyclosporine. These
results are not consistent with a previously published study
in patients with aplastic anemia, where significantly more
patients taking cyclosporine had an over 33% increase in
serum creatinine above baseline and ULN. However, it
should be noted that 56% of patients in that study received
deferasirox at 20 mg/kg/day or over.31
In our study, 2 patients had an increase in alanine amino-
transferase over 10 times ULN on one occasion. Levels
returned to normal in one patient following temporary dis-
continuation of the study drug and the study drug was not
modified in the second patient who completed 52 weeks of
treatment with ALT values below 2 times ULN. Although a
transient increase in liver enzymes has been reported as an
AE with deferasirox, a decrease in median alanine amino-
transferase over 12 months of deferasirox treatment has also
been reported.4
The impact of iron chelation on long-term outcomes of
patients with iron overload undergoing allo-HSCT has not
been evaluated in prospective randomized trials. However,
recently published studies analyzed the impact of iron chela-
tion with deferasirox on patient outcome.29,30,32 Visani et al.
have reported 8 patients with incomplete hematopoietic
reconstitution after HSCT who were treated with
deferasirox; all patients experienced an increase in hemoglo-
bin levels followed by transfusion independence.29 The
mechanisms underlying how deferasirox could induce
hematologic improvement have yet to be clarified.
Reduction in oxidative stress, a state that has a variety of
inhibitory effects on erythroid and hematopoietic function,
has been proposed as a possible explanation.33
In the study by Sigvin et al.,80 allo-HSCT patients with iron
overload were retrospectively analyzed.30 The patients were
divided into two groups: those who did not receive any
chelator treatment due to potential side effects or compli-
ance problems and who were treated by phlebotomy
(Group 1) and those who received deferasirox treatment
(Group 2). In univariate and multivariate analysis, patients in
Group 1 showed poorer overall survival compared to those
in Group 2 with an increase in risk of death (HR: 3.22, min-
max: 1.67-6.23, P=0.001 vs. HR: 3.51, min-max: 1.75-6.99,
P<0.001, respectively).
A second retrospective study of 158 adult patients who
underwent allo-HSCT reported that after a median follow
up of 18 months, the 5-year overall survival probability was
significantly higher for patients with serum ferritin below
500 ng/mL at the time of transplant than for those with
serum ferritin 500-2500 ng/mL or over 2500 ng/mL
(P=0.002) due to higher transplant-related mortality in the
patients with serum ferritin over 2500 ng/mL (P=0.04).32 The
patients who had received iron chelation had a significantly
better overall 5-year survival than non-chelated patients
(P=0.008) and experienced significantly less disease relapse
(P=0.012). 
In conclusion, deferasirox at 10 mg/kg/day administered
for 52 weeks post transplant resulted in a significant reduc-
tion in median serum ferritin and median LIC in 22 adult
patients who had undergone HSCT at least six months
before. The majority of AEs related to deferasirox were mild
or moderate, and the safety profile of deferasirox was simi-
lar to that reported in previous studies of patients with trans-
fusional hemosiderosis.2,3 
Additional studies are warranted to determine the exact
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prognostic role of iron overload in allo-HSCT and the impact
of iron chelation with deferasirox on long-term outcomes in
patients with hematologic malignancies and iron overload
undergoing allo-HSCT.
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